The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Really decent buy volume today, 2.2m+, this could push us through £2 again for close. Trek
Interesting appt? Not surprising given VAs holding but feels like a kick up the backside! Time to get the SP moving HZD else we will seek returns from our buyout specialist on the inside. I expect a positive market response to this. It was also an 0700 RNS not a glum end of day BoD change announcement. Trek, making of it what I will.
Drop another 10p and I’m back in. Excellent company, as is Abcam who make come back with another offer.
Looks like Woody still selling and valueact hoovering up everything. They were 5% not long ago. Not sure how much has been otc through broker as volumes seem low. I get woody selling to cover for elsewhere but VA are building a big position here. I wonder why, someone else on their books with a good nose, nudge nudge wink wink wink, you know what I mean! Lol! Trek
Holding up well above two quid support. Well done to all that got in at 150-160, Trek included and obviously those long termers who always seem to win the race. Anyways, all that aside there is sd all to report, nothing happening, all v quiet, fking dead parrot! Buy! Trek.
Results were at top end. Woody now selling, prob to cover elsewhere, but SP reacting positively. Must be takers. Mmmm.... things still looking good here for a bid and if not it’s still looking even better for longer term. Trek, win win. IMO obviously, lol!
Good luck to all existing holders for the results announcement on Monday 17th Sept!
Poor trading statement from Abcam today and given a weak outlook. Looks like it’s run out of organic steam and needs to be more accretive. Trek
Think so we now have a new insti aboard with 5% from out of the blue. HZD is a great co with takeover potential, either way I think it will do very well and now there is 5% less float. The low £2's could well be the new bargain territory. I am happy to hold this one long term and if she goes so be it. I will put the money into a divi stock. Unusual to be so comfortable with an AIM share. Trek
Now regret cashing in 85% of my stake at 190, but it's not a propitious time to be too greedy. Probably have to adjust re-entry point from 156?
Just checked gsk down but will now turn due to latest rns. Wish horizon would drop brilliant long term stock
Yep I know about the rise but it’s partly based on a few phase 3 drugs doing well. Also graph wise thier high was 17. Very good divs as well 80p for the year.
Trying to keep with defensive stocks for now and am thinking of selling what I have In October if I can move out without loss. Then wait to see what happens with brexit and a high market.
Careful in GSK. Share price climbed 23% in a short span of time, about 6 months.
I like the rest on here, enjoy, I hope dealing in shares. One thing that is starting to concern me is the upward trend now.
And knowing the way the merdochs of this world operate I will not be surprised if there is a major correction by end of October. Before you say it I’m not trying scare tactics. But know the way these low life’s operate. Please be aware rather than have all your eggs in the basket. No doubt I’ll be run over tomorrow Ha!
Just back into Glaxo. large buys after hours. Abcam still to dear.
Still way to high for my liking. Will get back in at about 1.85 (I hope).
Just a collaboration...doesn't justify the hike(to me). In the end, SP will be ruled by "how much money can we make"? last update was a warning on profit though. hope to get in below 181p again but that depends on what range it will be trading at till year end.
Article below from Cambridge Network.....sorry thought the link was at the bottom of post. Agree should be RNS.
https://www.cambridgenetwork.co.uk/news/horizon-collaboration-single-cell-rnaseq-linked-crispr/
Trek, finger trouble!
TrekMadone, where does this information come from? It is clearly an RNS, but this has not been reported here on LSE. It is clearly very good news and explains todays SP rise.
I said I’d wait until sep tem 8th that should of read 18th bit of a headine saying how well they had done but strip out the aqussision and they have dropped a mil. So that may bring the sp back a bit.
Thanks for that trek . It certainly doesn’t justify the lift in the sp as it’s another tool which in itself is great for the future.
Feeling a lot easier now as I still want to buy back in. the price in my opinion is about 40p to much. So will wait for the inevitable drop.
28/08/2018
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.
Co-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation
Single cell RNAseq-linked pooled CRISPR screening offers unparalleled depth of screening data and biological insight
New platform will further enhance Horizon’s CRISPR screening capabilities
As part of this collaboration, Horizon will lead the development and application of single cell RNAseq-linked pooled CRISPR screening using a key discovery paradigm of the pharma partner. Horizon will use the development process, acquired infrastructure, and optimization data in order to further develop and improve these tools to offer to future partners, as part of its research services operations.
Functional genomic screening with CRISPR-Cas9 technology has provided a powerful and precise way to identify and validate novel drug targets, and to elucidate unknown drug mechanisms. The depth of biological insight possible from Horizon’s single cell RNAseq-linked CRISPR screening platform will allow researchers to ask far more complex experimental questions and speed up the time from discovery to validation by integrating the effect of gene editing with complex phenotypic signature mapping. With this technology, pathways, biomarkers and cell function can all be studied and revealed with ultra-rich data.
Horizon’s pooled format screens offer researchers access to highly robust whole-genome level analyses that yield outstanding data quality. Whilst this approach has proven a potent research tool, it is currently challenging to adequately multiplex the analysis from these screens to evaluate complex biological phenomena. Coupling pooled screening to single cell RNAseq however, allows the opportunity to address the impact of CRISPR-based gene modification on a global transcriptomic level, at single cell resolution. This enables customers to address critical gaps in target identification and validation as they work to develop novel and more effective drug therapies.
“Pooled CRISPR-Cas9 knockout screens have rapidly become an important tool in novel drug target identification and validation. Horizon continues to innovate in this important area, having launched our CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) screening service in 2017, and through the development of RNAseq-linked CRISPR screening,” commentedTerry Pizzie, Chief Executive Officer, Horizon Discovery. “The co-development of this tool with a major pharma partner provides a substantive advance to Horizon’s already world-leading screening capabilities, offering our customers cutting-edge solutions not available elsewhere.”
More information about Hori
Yep it’s up 16% on sod all vol. makes no sense at all. One of the MMs must have fked up somewhere or there is a big sell instruction which usually sends the price higher to flush out buyers. But it’s probably the former. Trek, talking down our own rise. There’s a laugh!
There’s a tiddlers frenzy going on at the moment. Not a big fish in sight thank god.